Objective To compare the current trcmment of intertrochanteric fracture fixation commonly used in the two systems:proximal femoral nail(PFN-A)and the dynamic hip screw(DHS)of clinical efficacy and evaluate the treatment of the two intertroehanteric fracture of the gifted bad.Methods The clinical use on closed reduction and traction,respectively PFN-A with DHS and the treatment of intertrochanteric fracture patients with 106 cases and 115 cases,compared with its ease of operation,and the effect of surgery,postoperative complications.Results The clinical material demonstrated that in after PFN-A treatment thighbone thick pmsperom bone fracture technique,technique,the complication is short in DHS.Conclusion PFN-A well-designed,with simple anti-rotation indeed,surgical trauma,less bleeding,fewer complications,etc.,is the treatment of intertrochanteric fracture fixation one of the ideal.

85%) in 18 patients (21.4%) and a partial resection (

Objective To evaluate the value of early diagnosis and follow-up of bleeding and necrotizing pancreatitis by ultrasound.Methods 52 cases with bleeding and necrotizing pancreatitis confirmed by operation and pathology were examined by ultrasound. The pancreas were observed section by section in the blood vessel surrounding the pancreas acted as the mark under reduced the influence of gas in gastro-intestine and using adopting protruding probe with high resolution and compounding scanning technique in multi-posture. Results The accurate rate of diagnosis by ultrasound was 92%(48/52).During the follow-up period, pseudocysts and other complications were found in 9 cases, all cases recovered gradually after operations and treatment of symptoms except 3 cases who died caused by complications such as multiple organ dysfunction. Conclusion Ultrasound can identify bleeding and necrotizing pancreatitis early and also can regard as a significant follow-up method.

PURPOSE: Pigment epithelium-derived factor (PEDF) is a recently discovered antiangiogenesis protein. PEDF possesses powerful anti-inflammatory, antioxidative, antiangiogenic, and antifibrosis properties. It has been reported that PEDF can regulate vascular endothelial growth factor (VEGF) expression. This study aimed to evaluate whether recombinant PEDF protein could attenuate allergic airway inflammation and airway remodeling via the negative regulation of VEGF using a murine model of chronic ovalbumin (OVA)-induced asthma and BEAS-2B human bronchial epithelial cells. METHODS: In an in vivo experiment, mice sensitized with OVA were chronically airway challenged with aerosolized 1% OVA solution for 8 weeks. Treated mice were given injections of recombinant PEDF protein (50 or 100 microg/kg body weight) via the tail vein. In an in vitro experiment, we investigated the effects of recombinant PEDF protein on VEGF release levels in BEAS-2B cells stimulated with IL-1beta. RESULTS: Recombinant PEDF protein significantly inhibited eosinophilic airway inflammation, airway hyperresponsiveness, and airway remodeling, including goblet cell hyperplasia, subepithelial collagen deposition, and airway smooth muscle hypertrophy. In addition, recombinant PEDF protein suppressed the enhanced expression of VEGF protein in lung tissue and bronchoalveolar lavage fluid (BALF) in OVA-challenged chronically allergic mice. In the in vitro experiment, VEGF expression was increased after IL-1beta stimulation. Pretreatment with 50 and 100 ng/mL of recombinant PEDF protein significantly attenuated the increase in VEGF release levels in a concentration-dependent manner in BEAS-2B cells stimulated by IL-1beta. CONCLUSIONS: These results suggest that recombinant PEDF protein may abolish the development of characteristic features of chronic allergic asthma via VEGF suppression, providing a potential treatment option for chronic airway inflammation diseases such as asthma.
Airway Remodeling ; Animals ; Asthma ; Bronchoalveolar Lavage Fluid ; Collagen ; Eosinophils ; Epithelial Cells ; Goblet Cells ; Humans ; Hyperplasia ; Hypertrophy ; Inflammation* ; Lung ; Mice* ; Muscle, Smooth ; Ovalbumin ; Ovum ; Tail ; Vascular Endothelial Growth Factor A* ; Veins